ReviewVascular pharmacology2019
Linking diabetic vascular complications with LncRNAs.
Review in Vascular pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Causal insights into major risk factors for diabetic kidney disease: a comprehensive meta-analysis and Mendelian randomization study.Renal failure · 2025Pooled it
- Metabolic memory: mechanisms and diseases.Signal transduction and targeted therapy · 2024Review
- Research progress onFrontiers in pharmacology · 2024Review
- Facile Synthesis of MXene-TiMolecules (Basel, Switzerland) · 2023Article
- Profile analysis of differentially expressed long non‑coding RNAs in metabolic memory induced by high glucose in human umbilical vein endothelial cells.Experimental and therapeutic medicine · 2023Article
- Long noncoding RNA SNHG1 alleviates high glucose-induced vascular smooth muscle cells calcification/senescence by post-transcriptionally regulating Bhlhe40 and autophagy via Atg10.Journal of physiology and biochemistry · 2023Article
- Angiotensin II-Induced Long Non-Coding RNACells · 2021Article
- lncRNA DRAIR is downregulated in diabetic monocytes and modulates the inflammatory phenotype via epigenetic mechanisms.JCI insight · 2021Article
- A primer on metabolic memory: why existing diabesity treatments fail.Clinical kidney journal · 2021Review
- Emerging Role of Long Non-Coding RNAs in Diabetic Vascular Complications.Frontiers in endocrinology · 2021Review
- Metformin, Macrophage Dysfunction and Atherosclerosis.Frontiers in immunology · 2021Review
- lncRNA ZEB1-AS1 is downregulated in diabetic lung and regulates lung cell apoptosis.Experimental and therapeutic medicine · 2020Article
- Significance of Soluble CD93 in Type 2 Diabetes as a Biomarker for Diabetic Nephropathy: Integrated Results from Human and Rodent Studies.Journal of clinical medicine · 2020Article
- SIRT1 Antagonizes Oxidative Stress in Diabetic Vascular Complication.Frontiers in endocrinology · 2020Review
- Long noncoding RNAAutophagy · 2020Article
- Metabolism, Obesity, and Diabetes Mellitus.Arteriosclerosis, thrombosis, and vascular biology · 2019Article
- Epigenetics and Type 2 Diabetes Risk.Current diabetes reports · 2019Review
- Epigenetics and epigenomics in diabetic kidney disease and metabolic memory.Nature reviews. Nephrology · 2019Review
- Long Non-Coding RNA in Vascular Disease and Aging.Non-coding RNA · 2019Review
- A Novel Angiotensin II-Induced Long Noncoding RNA Giver Regulates Oxidative Stress, Inflammation, and Proliferation in Vascular Smooth Muscle Cells.Circulation research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Diabetes leads to markedly accelerated rates of many associated macrovascular complications like hypertension and atherosclerosis, and microvascular complications like nephropathy and retinopathy. High glucose, the hallmark of diabetes, drives changes in vascular and inflammatory cells that promote the development of these complications. Understanding the molecular processes involved in the development of diabetes and its debilitating complications can lead to much needed newer clinical therapies. Recently, long-noncoding RNAs (lncRNAs) have been shown to be important in the biology of vascular cells and there is growing evidence that lncRNAs are also involved in the cell biology relevant to diabetic vascular complications. In this review, we provide an overview of lncRNAs that function in vascular cells, and those that have been linked to diabetic complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.